Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The potential public health and economic benefit of an mRNA-based RSV vaccine, mRNA-1345, among high-risk adults aged 18-59 years in the US: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster presented at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Ghaswalla P, Joshi K, Hicks KA, Xiao Z, Fust K, Kohli M, Weinstein MC. Cost-effectiveness of Moderna's RSV vaccine, mRNA-1345 (mRESVIA) compared to no vaccination in adults 18-49 years at increased risk of severe RSV disease in the United States. Presented at the US Advisory Committee on Immunization Practices Respiratory Syncytial Virus Vaccines - Adults Work Group; May 2025. Atlanta, GA.

Ghaswalla P, Joshi K, Hicks K, Xiao Z, Fust K, Kohli M, Weinstein MC. Preliminary cost-effectiveness of Moderna's RSV vaccine, mRNA-1345 (mRESVIA) compared to no vaccination in adults 50-59 years at increased risk of severe RSV disease in the United States. Presented at US Advisory Committee on Immunization Practices Respiratory Syncytial Virus Vaccines – Adult Work Group; January 24, 2025. Atlanta, GA.

Chen H, Lu D, Xiao Z, Li S, Zhang Wen, Luan X, Zhang W, Zheng G. Comprehensive applications of the artificial intelligence technology in new drug research and development. Health Inf Sci Syst. 2024 Aug 8;12(1):41. doi: 10.1007/s13755-024-00300-y